Drug Herceptin appears
to Cure HER-2 Breast Cancer According to Journal
October 20th 2005
appears to be a cure for women with HER II positive breast cancer, which
accounts for 20 to 25 percent of breast cancer cases. Women treated
with Heceptin had a 46% reduction in reoccurring breast cancer. It is
proving to be highly effective against an aggressive form of breast
cancer that tends to strike younger women.
England Journal of Medicine reported that the drug Herceptin, which was
licensed only for advanced breast cancer, has effectively targeted a
specific protein that halted the spread of the disease.
usher in a new era in cancer research where drugs are tailored made to
target specific receptors identified for specific diseases. The old
method of research was based on trial and error where researchers screen
thousand of compounds to find one that works. Also, this particular
drug targets only diseased cells.
It is rare
that the New England Journal of Medicine (NEJM)
uses such definitive language in describing a potential cure. The
results are, it concludes, “revolutionary, not evolutionary”. “Our care
of patients with HER II positive breast cancer must change today.”
The generic name for Herceptin is
traastuzumab. The drug is not a chemotherapy drug. It is a hormone or
special type of protein that attacks a protein in a tumor cell.
Herceptin is made by Genetech. The common therapy is to excise the
tumors and implement a combination chemotherapy and Herceptin
There were three Herceptin research
studies that involved 6500 women with early-stage breast cancer. One
study was funded by Hercetpin’s European marketer, Roche, and the others
were sponsored by the National Cancer Institute. Herceptin was approved
in 1998 for advanced breast cancer.
By Dan Wilson
Best Syndication Staff Writer
Books on Breast Cancer
Keywords and misspellings: Her-2 her 2 canser sells